1-3 of 3
Baruch Bulvik
Close
Sort by
Journal Articles

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

Michal Abraham, PhD, Galia Oberkovitz, PhD, Baruch Bulvik, Klein Shiri, Hanna Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, MD, Abi Vainstein, MD, Eyal Benami, Rotem Golan, Eithan Galun, Yoseph Caraco, Reuven Or, MD, Amnon Peled
Journal: Blood
Blood (2017) 130 (Supplement 1): 660.
https://doi.org/10.1182/blood.V130.Suppl_1.660.660
Published: 2017
Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

Michal Abraham, PhD, Shiri Klein, Baruch Bulvik, Hanna Wald, Dvora Holam, Lola Weiss, Katia Beider, PhD, Orly Eizenberg, Ori Wald, MD PhD, Abraham Avigdor, MD, Ohad Benjamini, MD, Eithan Galun, MD, Arnon Nagler, Yaron Pereg, PhD, Amnon Peled, PhD
Journal: Blood
Blood (2016) 128 (22): 767.
https://doi.org/10.1182/blood.V128.22.767.767
Published: 2016
Journal Articles

Iron Homeostasis and Methionine-Centered Redox Cycle in Aged Rat Spleen.

Baruch Bulvik, Eduard Berenshtein, MD, PhD, Abraham M. Konijn, PhD, Mottie (Mordechai) Chevion, PhD
Journal: Blood
Blood (2009) 114 (22): 4049.
https://doi.org/10.1182/blood.V114.22.4049.4049
Published: 2009